These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23705284)

  • 1. [Canagliflozin. For treating diabetes].
    Sabourin G
    Perspect Infirm; 2013; 10(3):59. PubMed ID: 23705284
    [No Abstract]   [Full Text] [Related]  

  • 2. [SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
    Seufert J
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S52-8. PubMed ID: 24481633
    [No Abstract]   [Full Text] [Related]  

  • 3. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
    Matthaei S
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S59-64. PubMed ID: 24481634
    [No Abstract]   [Full Text] [Related]  

  • 4. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canagliflozin: Improving diabetes by making urine sweet.
    Vouyiouklis M
    Cleve Clin J Med; 2013 Nov; 80(11):683-7. PubMed ID: 24186885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin, alogliptin benzoate, and ospemifene.
    Hussar DA; Frimpong JO
    J Am Pharm Assoc (2003); 2013; 53(4):442-7. PubMed ID: 23892821
    [No Abstract]   [Full Text] [Related]  

  • 7. Canagliflozin: a new drug for type 2.
    Goldman-Levine J
    Diabetes Self Manag; 2013; 30(4):30, 32. PubMed ID: 23961597
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Nyirjesy P; Zhao Y; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin approved for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2013 May; 70(10):834. PubMed ID: 23640337
    [No Abstract]   [Full Text] [Related]  

  • 11. Canagliflozin: a new hope in the antidiabetic armamentarium.
    Katsi VK; Michalakeas CA; Grassos CE; Vamvakou GD; Lekakis JP; Tousoulis D; Stefanadis CI; Makris TK; Kallikazaros IE
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):216-20. PubMed ID: 24359233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. US approves "new class" of diabetes drug, under review in Canada.
    Lange-Chenier H
    CMAJ; 2013 Jul; 185(10):E470. PubMed ID: 23734031
    [No Abstract]   [Full Text] [Related]  

  • 13. Treating type 2 diabetes with canagliflozin.
    Van Gilder D; Jungemann S
    S D Med; 2013 Jul; 66(7):280-1. PubMed ID: 23957114
    [No Abstract]   [Full Text] [Related]  

  • 14. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
    Sha S; Devineni D; Ghosh A; Polidori D; Chien S; Wexler D; Shalayda K; Demarest K; Rothenberg P
    Diabetes Obes Metab; 2011 Jul; 13(7):669-72. PubMed ID: 21457428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
    Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Stein P; Desai M; Shaw W; Jiang J; Vercruysse F; Meininger G; Matthews D
    Am Heart J; 2013 Aug; 166(2):217-223.e11. PubMed ID: 23895803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach.
    Gebel E
    Diabetes Forecast; 2013 Jun; 66(6):32-4. PubMed ID: 23802291
    [No Abstract]   [Full Text] [Related]  

  • 17. New diabetes drugs go beyond insulin to flush out excess sugar.
    Heger M
    Nat Med; 2011 Jun; 17(6):636. PubMed ID: 21647124
    [No Abstract]   [Full Text] [Related]  

  • 18. What is the place of new SGLT-2 inhibitors in therapy and on the formulary?
    Mehr SR; Zimmerman MP
    Am J Manag Care; 2014 Mar; 20(4 Spec No.):E1. PubMed ID: 25618509
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 2 diabetes mellitus and Invokana: an FDA approved drug.
    Akhtar N
    Curr Diabetes Rev; 2013 Nov; 9(6):478-90. PubMed ID: 24160357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.